Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 in advanced or metastatic solid tumors
NCT04370587Phase 2Recruiting
- Sponsor
- ImmVira
- Start
- Sep 2020
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of MVR-T3011 in melanoma, head and neck squamous cell carcinoma (HNSCC), sarcoma, cutaneous squamous cell carcinoma (cSCC), non-small cell lung cancer (NSCLC), sponsored by ImmVira. Started Sep 2020; status: recruiting.
02
Drugs
MVR-T3011
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)sarcomacutaneous squamous cell carcinoma (cSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04370587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370587.